Skip to main content
Jennie Crews, MD, Oncology, Palo Alto, CA

JennieRCrewsMD

Oncology Palo Alto, CA

Associate Chief Medical Officer, Ambulatory Care, Stanford Health Care Chief Medical Officer, Stanford Medicine Partners

Dr. Crews is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Crews' full profile

Already have an account?

  • Office

    300 Pasteur Dr
    Palo Alto, CA 94304
    Phone+1 650-723-4000

Education & Training

  • USC Marshall School of Business
    USC Marshall School of BusinessMaster Medical Management (MMM), Business, 2015 - 2016
  • Duke University Hospital
    Duke University HospitalFellowship, Hematology and Medical Oncology, 1993 - 1995
  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine, 1990 - 1993
  • Duke University School of Medicine
    Duke University School of MedicineClass of 1990

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2022 - 2026
  • WA State Medical License
    WA State Medical License 2012 - 2026
  • NC State Medical License
    NC State Medical License 1992 - 2025
  • AK State Medical License
    AK State Medical License 2013 - 2021
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • Fellow (FACP) American College of Physicians, 2002

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • ELP1 Loss Disrupts Protein Homeostasis to Promote SHH Medulloblastoma
    ELP1 Loss Disrupts Protein Homeostasis to Promote SHH MedulloblastomaJune 1st, 2020
  • Cysteine Is Required for Preventing Ferroptosis in Pancreatic Cancer
    Cysteine Is Required for Preventing Ferroptosis in Pancreatic CancerJune 1st, 2020
  • Specific Helical Domain Contacts Mediate PARP1 Inhibitor Activity
    Specific Helical Domain Contacts Mediate PARP1 Inhibitor ActivityJune 1st, 2020
  • Join now to see all

Professional Memberships